A biotechnology company is designing a vaccine to protect against the newly emergent avian flu to provide more sustained protection like seasonal flu vaccines. . . . → Read More: Avian Flu Vaccine with Longer Protection in Development
|
|||||
|
|
The biotechnology company Halozyme Therapeutics Inc. is licensing its technology for making infusion drugs deliverable with injections to two more drug makers. . . . → Read More: Drug Delivery Technology Licensed in $2B Deals A company producing synthesized DNA for medical and other biotechnology applications is raising €11 million ($US 13 million) in its first venture funding round. . . . → Read More: Synthetic DNA Start-Up Raises $13M in Early Funds Results from a large-scale clinical trial show a synthetic antibody, when added to standard treatments, reduces asthma attacks and improves lung functioning. . . . → Read More: Trial Shows Antibody Effective Against Asthma A new enterprise developing treatments using gene editing to eliminate HIV infections received $10 million in its seed funding round. . . . → Read More: Start-Up Lands $10M for Gene-Editing HIV Treatments Outdoor tests of a genetically engineered diamondback moth, a difficult agricultural pest, altered to stop reproducing and collapse the species, are about to get underway. . . . → Read More: Field Tests of Genetically Modified Moths to Begin The Food and Drug Administration stopped two clinical trials testing genetically engineered T-cells from the immune system to treat leukemia, after a participant in one trial died. . . . → Read More: Engineered T-Cell Trials Stopped after Patient Death  Comments are closed  Regulations  biomedical, biotechnology, cancer, clinical trials, FDA, life sciences, pharmaceuticals A new clinical trial began in the U.K. in a test of an experimental drug to treat schizophrenia associated with Alzheimer’s disease. . . . → Read More: Trial Underway Testing Alzheimer’s-Schizophrenia Drug Comments are closed New products biomedical, biotechnology, clinical trials, Europe, licensing, life sciences, pharmaceuticals, psychiatric, U.K. A simpler technique using nanoscale particles was shown in lab tests to deliver messenger RNA to reprogram cells for gene therapies, including changes in T-cells in the immune system now approved to treat a type of leukemia. . . . → Read More: Simple Cell Programming Designed for Gene Therapies One comment - (Comments are closed) New products biomedical, biotechnology, cancer, genomics, life sciences, materials science, nanotechnology, patent, pharmaceuticals, physical sciences, stem cells, university A company developing personal cancer therapies that genetically engineer a patient’s immune system cells is being acquired in a deal valued at $11.9 billion. . . . → Read More: Engineered T-Cell Company Acquired for $11.9 Billion One comment - (Comments are closed) Finance biomedical, biotechnology, cancer, clinical trials, entrepreneurs, equity, investment, licensing, life sciences, merger, NIH, pharmaceuticals |
A Thinking Person’s Artificial Intelligence Do You Want Your Bacon CRISPR? Health Care, Precisely One Person at a Time Let Guinea Pigs be Guinea Pigs Look Out Pharma. The Tech Industry is After You |
|||
|
Copyright © 2017 Technology News and Literature - All Rights Reserved Powered by WordPress & Atahualpa |
|||||
